TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04237441

Intervention type: OTHER
Intervention: number of participants with surgical complications
Description: observation before and after multidisplinary team conference (MDT) was implemented

Intervention type: OTHER
Intervention: number of participants with surgical complications
Description: observation before and after multidisplinary team conference (MDT) was implemented
Study: NCT02024867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole
Description: 3 versus 10 days of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole
Description: 3 versus 10 days of drug
Study: NCT04751344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
Study: NCT02506140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Acetylsalicylic acid
Description: This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel and Acetylsalicylic acid
Description: This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
Study: NCT04053959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI assisted insulin system
Description: The patients receive the insulin regime set by AI assisted insulin titration system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician based insulin regime
Description: Patients receive the insulin regime recommended by physicians
Study: NCT05909774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test with Atalante exoskeleton in continuous walk type
Description: The continuous walk is smoother and more physiologic than the push and swing walk
Study: NCT02374658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Through the Arts Intervetion
Description: A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
Study: NCT01726673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sham
Study: NCT01788579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-media WINGS
Description: This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caseworker Delivered WINGS
Description: The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
Study: NCT03730766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT00984607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: barium sulfate tablet
Description: After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
Study: NCT02753686

Intervention type: DRUG
Intervention: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant

Intervention type: DRUG
Intervention: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
Study: NCT02702531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloShield Defogging and Cleaning System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloShield Defogging and Cleaning System
Study: NCT02370095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treprostinil Inhalation Solution
Description: Treprostinil inhalation solution administered as blinded marketed product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
Study: NCT00137696

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with inactivated polio vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with inactivated polio vaccine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of serum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of serum
Study: NCT00581828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
Study: NCT02822300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-74_R84-086)
Study: NCT03186014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully covered irradiation stent
Description: A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
Study: NCT00070252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given orally (PO)
Study: NCT05532267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Description: an immediate release film-coated tablet containing 750 mg Ciprofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciproxin 750 mg
Description: an immediate release film-coated tablet containing 750 mg Ciprofloxacin
Study: NCT00640640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pascal Dynamic Contour Tonometer
Description: Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
Study: NCT00997425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door cover/Floor cover
Description: Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.~Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door.
Study: NCT03147313

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MTS Medical UG Orthogold 100
Description: 300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MTS Medical UG Orthogold 100
Description: 300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Extracorporeal shock wave treatment will be faked.
Study: NCT02427724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2.5%/prilocaine 2.5% topical anesthetic
Study: NCT03264209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart After-Care (Mobile health)
Description: Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
Study: NCT02427724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 7%/tetracaine 7% topical anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vehicle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-switched 532nm Laser
Study: NCT03946033

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunoscore Colon Test
Description: Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
Study: NCT04720846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-based physical therapy
Description: Matrix-based physical therapy will be physical therapy that is based on the matrix categorization of the patient (stiff vs. mobile hips, weak vs. strong hips) and involves instructions on the amount of time that should be spent doing stretching and strengthening therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care physical therapy
Description: Physical therapy that is being conducted as standard-of-care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-care physical therapy
Description: Physical therapy that is being conducted as standard-of-care
Study: NCT02427724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-switched 532nm Laser

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Q-switched 532nm Laser
Study: NCT02312765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AirCare App
Description: Tablet software to encourage adherence and support
Study: NCT02178046

Intervention type: DEVICE
Intervention: optical measurements
Description: Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
Study: NCT02121288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
Study: NCT02389205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio group
Description: kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc.
Study: NCT02121288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
Study: NCT00755157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
Study: NCT02135146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte 3ml/kg/hr group
Description: This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
Study: NCT03653572

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound exam
Description: Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
Study: NCT00136825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02135146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte 6ml/kg/hr group
Description: This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
Study: NCT02063854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NE-58095 IR
Description: NE-58095 IR tablets
Study: NCT00571207

Intervention type: DEVICE
Intervention: On-site oral fluid screening devices
Description: Comparison of screening device results to oral and/or blood sample results

Intervention type: DEVICE
Intervention: On-site oral fluid screening devices
Description: Comparison of screening device results to oral and/or blood sample results

Intervention type: BEHAVIORAL
Intervention: Checklist: drug recognition expert
Description: Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases

Intervention type: BEHAVIORAL
Intervention: Checklist: drug recognition expert
Description: Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
Study: NCT04401839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin IV shot
Description: Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin IV shot
Description: Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin IV drip
Description: administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amr maneuver
Description: sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds
Study: NCT04178993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methamphetamine
Description: In each arm, subjects will receive doses of methamphetamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine
Description: In each arm, subjects will receive doses of methamphetamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: In each arm, subjects will receive methylphenidate capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: In each arm, subjects will receive methylphenidate capsules.
Study: NCT02063854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 IR Placebo
Description: NE-58095 IR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 IR Placebo
Description: NE-58095 IR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 IR Placebo
Description: NE-58095 IR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 IR Placebo
Description: NE-58095 IR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 IR Placebo
Description: NE-58095 IR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 IR Placebo
Description: NE-58095 IR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR
Description: NE-58095 DR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR
Description: NE-58095 DR tablets
Study: NCT04178993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: In each arm, subjects will receive placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: In each arm, subjects will receive placebo capsules.
Study: NCT02063854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR
Description: NE-58095 DR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR
Description: NE-58095 DR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR
Description: NE-58095 DR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR
Description: NE-58095 DR tablets
Study: NCT04178993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Subjects will receive duloxetine capsules in the duloxetine arm.
Study: NCT03983772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RS blend
Description: The intervention is a proprietary resistant starch blend.
Study: NCT02063854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR Placebo
Description: NE-58095 DR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR Placebo
Description: NE-58095 DR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR Placebo
Description: NE-58095 DR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR Placebo
Description: NE-58095 DR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR Placebo
Description: NE-58095 DR placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR Placebo
Description: NE-58095 DR placebo-matching tablets
Study: NCT03983772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RS blend
Description: The intervention is a proprietary resistant starch blend.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RS blend
Description: The intervention is a proprietary resistant starch blend.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is starch.
Study: NCT01556061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DMAC
Description: The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
Study: NCT02063854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NE-58095 DR Placebo
Description: NE-58095 DR placebo-matching tablets
Study: NCT01482039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sequential ultrasound
Description: Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: Obtain 3 transvaginal ultrasound cervical length measurements
Study: NCT01462084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Description: Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Description: Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.